中科生物(01237.HK)被美國裁反傾銷和反補貼稅令 保證金費率達54.43%
中科生物(01237.HK)公布,於1月22日美國國際貿易委員會裁定,美國的一個行業受到從中國進口的木線條和木製品(該等產品被美國商務部確定存在補貼和在美國以低於公允價值出售)的損害。
根據美國國際貿易委員會的肯定性裁定,商務部將對從中國進口的該等產品發出反傾銷和反補貼稅令。美國海關和邊境保護局將向集團相關產品的進口商收取總計54.43%的現金存款。
集團旗下全資附屬公司漳平木村被裁定其若干出口至美國之木製品之加權平均傾銷率及補貼率分別為44.6%及20.56%,商務部將指示美國海關和邊境保護局將向集團產品之進口商收取費率合共為54.43%之保證金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.